fbpx

Essilor and Luxottica Take Steps Toward Formal Merger

The March 22 Directors meeting of Essilor International have approved the transfer of its activities and shareholdings to Delamare Sovara, its fully-owned subsidiary.  Delamare Sovara will subsequently be renamed to Essilor International.  Also, the share exchange of Luxottica shares by Delfin, for new Essilor shares was also approved.

These steps were taken subsequent to having obtained favourable opinions of the merger from employee shareholder groups. Discussions concerning the notification process of the transaction to anti-trust authorities are progressing, according to the company release.

The New Board of Directors, subject to shareholder’s approval in May, the new board will consist of the following;

  • Hubert SAGNIÈRES, Chairman and CEO of Essilor International
  •  Philippe ALFROID, Non-independent Director
  • Antoine BERNARD DE SAINT-AFFRIQUE, Independent Director
  • Maureen CAVANAGH, Director representing employee shareholders
  • Juliette FAVRE, Director representing employee shareholders
  • Henrietta FORE, Independent Director
  • Louise FRÉCHETTE, Independent Director
  • Yi HE, Director representing employee shareholders
  • Frank HENRIONNET, Director representing employees
  • Bernard HOURS, Independent Director
  • Annette MESSEMER, Independent Director
  • Marc ONETTO, Independent Director
  • Olivier PECOUX, Non-independent Director
  • Laurent VACHEROT, President and Chief Operating Officer of Essilor International
  • Jeanette WONG, Independent Director

For the complete press release click here.

Featured Posts

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read More

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read More

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read More

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read More

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Learn More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

LE PARC: Discover the New Fall/Winter Collection 2023

Inspired by art, culture and creative freedom, LE PARC designs vibrant and sophisticated eyewear that highlights the identity of each individual.

Read more

Cone-Rod Dystrophy

A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa.

Read more